Stocks News

LAST PRICE
136.1900
TODAY'S CHANGE (%)
Trending Up3.6800 (2.7771%)

Bid / Lots
136.1000/ 2
Ask / Lots
136.4100/ 4
Open / Previous Close
132.8400 / 132.5100
Day Range
Low 131.3700
High 136.3400
52 Week Range
Low 83.7500
High 161.0000
Volume
123,843
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Ascendis to Spotlight Latest Updates for TransCon(TM) Rare Endocrinology Disease Portfolio at ENDO 2024, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: ASND
  
  Ascendis to Spotlight Latest Updates for TransCon(TM) Rare Endocrinology Disease Portfolio at ENDO 2024
  
  COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency (GHD), hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston.
May 22, 2024
- European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading, from 11:01AM ET on Wednesday May 22, 2024 by MT Newswires
  11:01AM ET on Wednesday May 22, 2024 by MT Newswires
  Companies Mentioned: FMS, GSK, TRIB, SQNS, GRFS, TRVG, VRNA, GNFT, MREO, BCYC, BNTX, BHP, SLN, EVAX, ASND, BDRX
  11:01 AM EDT, 05/22/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts fell Wednesday morning, declining 0.48% to 1,423.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by bi...
May 16, 2024
- --Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating, from 12:17PM ET on Thursday May 16, 2024 by MT Newswires
  12:17PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: ASND
  12:17 PM EDT, 05/16/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...
- DJ Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley, from 12:11PM ET on Thursday May 16, 2024 by Dow Jones
  12:11PM ET on Thursday May 16, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 16, 2024 12:11 ET (16:11 GMT)
May 15, 2024
- DJ Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald, from 8:37AM ET on Wednesday May 15, 2024 by Dow Jones
  8:37AM ET on Wednesday May 15, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 15, 2024 08:37 ET (12:37 GMT)

Today
- IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 42 minutes ago by Accesswire
  42 minutes ago by Accesswire
  Companies Mentioned: BPMC
- Insmed Prices $650 Million Public Offering, from 2 hours ago by MT Newswires
  2 hours ago by MT Newswires
  Companies Mentioned: INSM
- Insmed Announces Pricing of $650 Million Public Offering of Common Stock, from 4 hours ago by PR Newswire
  4 hours ago by PR Newswire
  Companies Mentioned: INSM
Yesterday
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 12:35PM ET on Wednesday May 29, 2024 by Accesswire
  12:35PM ET on Wednesday May 29, 2024 by Accesswire
  Companies Mentioned: BPMC
- Wolfe Research Adjusts Price Target on Insmed to $54 From $42, Maintains Outperform Rating, from 11:51AM ET on Wednesday May 29, 2024 by MT Newswires
  11:51AM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: INSM
- Morgan Stanley Adjusts Price Target on Insmed to $60 From $43, Maintains Overweight Rating, from 11:51AM ET on Wednesday May 29, 2024 by MT Newswires
  11:51AM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: INSM
- TD Cowen Adjusts Insmed Price Target to $67 From $45, Maintains Buy Rating, from 11:10AM ET on Wednesday May 29, 2024 by MT Newswires
  11:10AM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: INSM
- Goldman Sachs Adjusts Insmed Price Target to $74 From $49, Maintains Buy Rating, from 10:14AM ET on Wednesday May 29, 2024 by MT Newswires
  10:14AM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: INSM
- BofA Securities Adjusts Price Target on Insmed to $62 From $40, Maintains Buy Rating, from 9:49AM ET on Wednesday May 29, 2024 by MT Newswires
  9:49AM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: INSM
- Wells Fargo Adjusts Insmed Price Target to $77 From $55, Maintains Overweight Rating, from 9:43AM ET on Wednesday May 29, 2024 by MT Newswires
  9:43AM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: INSM

Ascendis Pharma A/S
NASDAQ:ASNDUnited States

Search Criteria

Today

Ascendis to Spotlight Latest Updates for TransCon(TM) Rare Endocrinology Disease Portfolio at ENDO 2024, from 4 hours ago by Dow Jones

May 22, 2024

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading, from 11:01AM ET on Wednesday May 22, 2024 by MT Newswires

May 16, 2024

--Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating, from 12:17PM ET on Thursday May 16, 2024 by MT Newswires

DJ Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley, from 12:11PM ET on Thursday May 16, 2024 by Dow Jones

May 15, 2024

DJ Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald, from 8:37AM ET on Wednesday May 15, 2024 by Dow Jones

Peers Headlines

Today

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 42 minutes ago by Accesswire

Insmed Prices $650 Million Public Offering, from 2 hours ago by MT Newswires

Insmed Announces Pricing of $650 Million Public Offering of Common Stock, from 4 hours ago by PR Newswire

Yesterday

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 12:35PM ET on Wednesday May 29, 2024 by Accesswire

Wolfe Research Adjusts Price Target on Insmed to $54 From $42, Maintains Outperform Rating, from 11:51AM ET on Wednesday May 29, 2024 by MT Newswires

Morgan Stanley Adjusts Price Target on Insmed to $60 From $43, Maintains Overweight Rating, from 11:51AM ET on Wednesday May 29, 2024 by MT Newswires

TD Cowen Adjusts Insmed Price Target to $67 From $45, Maintains Buy Rating, from 11:10AM ET on Wednesday May 29, 2024 by MT Newswires

Goldman Sachs Adjusts Insmed Price Target to $74 From $49, Maintains Buy Rating, from 10:14AM ET on Wednesday May 29, 2024 by MT Newswires

BofA Securities Adjusts Price Target on Insmed to $62 From $40, Maintains Buy Rating, from 9:49AM ET on Wednesday May 29, 2024 by MT Newswires

Wells Fargo Adjusts Insmed Price Target to $77 From $55, Maintains Overweight Rating, from 9:43AM ET on Wednesday May 29, 2024 by MT Newswires